Surgery for the treatment of localized prostate cancer

Similar documents
7. Prostate cancer in PSA relapse

Cancer research in the Midland Region the prostate and bowel cancer projects

Beyond the PSA: Genomic Testing in Localized Prostate Cancer

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?

Questions to ask my doctor: About prostate cancer

FAQ About Prostate Cancer Treatment and SpaceOAR System

Questions to Ask My Doctor About Prostate Cancer

PSA Screening for Prostate Cancer Information for Care Providers

Historical Basis for Concern

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Early Prostate Cancer: Questions and Answers. Key Points

2/14/09. Long Term Risk of Radiation Therapy for Clinically Localized Prostate Cancer. Radiation Therapy: Various Forms of Radiation Treatment

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

Prostate Cancer. Treatments as unique as you are

Treating Prostate Cancer

A918: Prostate: adenocarcinoma

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto

Robert Bristow MD PhD FRCPC

The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective

Roswell Park scientists and clinicians:

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon

Thomas A. Kollmorgen, M.D. Oregon Urology Institute

Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology

Prostate Cancer Treatment: What s Best for You?

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers

DIAGNOSIS OF PROSTATE CANCER

2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER

PATIENT GUIDE. Localized Prostate Cancer

Use Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa

A Woman s Guide to Prostate Cancer Treatment

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

4/8/13. Pre-test Audience Response. Prostate Cancer Screening and Treatment of Prostate Cancer: The 2013 Perspective

Treating Localized Prostate Cancer A Review of the Research for Adults

PCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:

An Introduction to PROSTATE CANCER

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

Individual Prediction

Does my patient need more therapy after prostate cancer surgery?

Radiation Therapy for Prostate Cancer: Treatment options and future directions

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

Prostate cancer A guide for newly diagnosed men

Use of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Does Radiation Treatment of Prostate Cancer Increase Risk for Rectal Cancer? The Perfect Storm

The PSA Controversy: Defining It, Discussing It, and Coping With It

Jurisdiction Virginia

Therapies for Prostate Cancer and Treatment Selection

SRO Tutorial: Prostate Cancer Treatment Options

Screening for Prostate Cancer

CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA

DOCTOr. Doctor to HIGHLIGHTS. issue NO. 3 VOLuMe NO. 1

Prostate Cancer Results Study Group 2014 Results Comparing Treatment of. About This Review Study

Radiation Therapy for Prostate Cancer

For further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.

1. What is the prostate-specific antigen (PSA) test?

Newly Diagnosed Prostate Cancer: Understanding Your Risk

Neoadjuvant and Adjuvant Hormone Therapy: How and When?

Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery

Localised prostate cancer

Advances in Diagnostic and Molecular Testing in Prostate Cancer

855-DRSAMADI or

The 4Kscore blood test for risk of aggressive prostate cancer

Implementation Date: April 2015 Clinical Operations

Prostate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?

Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine

Prostate Cancer Screening. A Decision Guide

HEALTH NEWS PROSTATE CANCER THE PROSTATE

Report with statistical data from 2007

Local Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153)

Prostate Cancer. Screening and Diagnosis. Screening. Pardeep Kumar Consultant Urological Surgeon

Prostate Cancer Action Plan: Choosing the treatment that s right for you

Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S

GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.

Prostate Cancer Patients Report on Benefits of Proton Therapy

Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer

Prostate Cancer 2014

Protons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D.

一 本 共 識 依 下 列 參 考 資 料 修 改 版 本 : 1. NCCN Clinical Practice Guidelines in Oncology- Prostate cancer V

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

Prostate cancer screening. It s YOUR decision!

Focal therapy for prostate cancer: seriously or seriously? Disclosures

PROTON BEAM THERAPY FOR PROSTATE CANCER. A Technology Assessment

Prostate cancer is the second most

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

The 4Kscore blood test for risk of aggressive prostate cancer

A New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY

Prostate Cancer Screening. A Decision Guide for African Americans

Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide

PSA screening in asymptomatic men the debate continues keyword: psa

Prostate Cancer. Dr Paula Wells Consultant Clinical Oncologist

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

Role of Radiation after Radical Prostatectomy Review of Literature

Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure

Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer

Description of Procedure or Service. gene_based_tests_for_screening_detection_or_management_of_prostate_cancer 4/2009 8/2015 8/2016 8/2015

Transcription:

Surgery for the treatment of localized prostate cancer Joseph Dall Era Division of Urology November 24, 2008 General Surgery Grand Rounds University of Colorado

Prostate Cancer Statistics 234,460 cases diagnosed annually 213,358 With localized disease (91%) Stage Gleason grade PSA Health status (age) Patient preferences (QOL) Informed Decision Surgery EBRT Brachy Tx cryotherapy Hormonal Tx active surveillance 37% 20% 24% Sommers BD et al. Predictors of patient preference and treatment choice for localized prostate cancer. Am Can Soc 2008. Jemal A et al. Cancer statistics, 2006.

Randomized Controlled Trials (RCTs) provide the best evidence for therapeutic decision making RCTs comparing primary treatment modalities for prostate cancer are EXTREMELY LIMITED. Most RCTs compare various interventions within a specific treatment modality (ie surgery with and without hormone therapy). Informed Decision

Signs of the coming Armageddon

Surgery Vs. Radiation Effectiveness in cancer treatment (can t look to RCTs) Staging Local control Overall survival Quality of life Complications from treatment Early Delayed Risk of secondary malignancies Cost

Staging Lymph nodes status Accuracy of gleason grading

98 men s/p RRP with + LNs Randomized to immediate ADT (LHRH agonist or orchiectomy) or observation median of 7 years follow up

Prostate cancer specific mortality Treatment Arm Total Died (disease specific) Hormone 47 3 Observation 51 16 2006 update: 12 years median follow up *37 pts in obs group received ADT for disease recurrence

Staging Concordance of PNBX and RP grade 1363 pts underwent PNBx and RP from 1992-2006 Pts receiving ADT excluded Undergraded: 53% 37% 20% Soloway MS et al. Trends in gleason score: concordance between biopsy and prostatectomy over 15 years. Urology 2008.

Surgery versus radiation In HIGH RISK DISEASE prostate cancer specific mortality Urology, 2006. 453 men with localized prostate cancer (Gleason 8) treated with, 26% RP 30% radiation 44% conservative (early hormonal tx or WW) retrospective cohort study Median follow up = 68 months for RP, 53 months for conservative and radiation

Results Overall Risk of Death: Median overall survival: 32% lower for RP compared to conservative tx 42% lower for RP compared to radiation 5.2 yrs for conservative tx 6.7 yrs for radiation 9.7 yrs for prostatectomy

Results Cancer specific death: 68% lower for RP compared to conservative tx 49% lower for RP compared to radiation

Surgery versus radiation prostate cancer specific mortality Tsai HK, D Amico AV et al. Cancer specific mortality after radiation therapy with short course hormonal therapy or radical prostatectomy in men with localized intermediate-risk to high-risk prostate cancer. Cancer 107:11 2006. retrospective study, mean followup 4.5 yrs 550 pts tx with XRT + ADT (6 months LHRH agonist + antiandrogen) 2690 pts tx with RP Risk factors: PSA > 10 ng/ml, Gleason 7-10, T2b or T2c

Surgery versus radiation prostate cancer specific mortality Tsai HK, D Amico AV et al. Cancer specific mortality after radiation therapy with short course hormonal therapy or radical prostatectomy in men with localized intermediate-risk to high-risk prostate cancer. Cancer 107:11 2006. XRT + HT RP

Surgery vs. Watchful Waiting Bill-Axelson A et al. Radical prostatectomy versus watchful waiting in early prostate cancer. NEJM. 2005 prospective, RCT 695 men with prostate cancer randomly assigned to RP (347) or WW (348). median 8.2 years followup

Surgery vs. Watchful Waiting Bill-Axelson A et al. Radical prostatectomy versus watchful waiting in early prostate cancer. NEJM. 2005 prospective, RCT 695 men with prostate cancer randomly assigned to RP (347) or WW (348). median 8.2 years followup

183 pts EBRT Colorectal complications of EBRT Mean f/u 39 months 43% 19% 3% 3 pts with rectal bleeding requiring colonoscopy and cauterization 1 pt with anal stricture requiring dilation under anesthesia Lesperance RN et al. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer. AM J Surg. 195:616. 2008.

Risk of secondary malignancies 243,082 men undergoing RP or radiation therapy 1988-2003 (SEER) Increased risk of bladder and rectal cancers for EBRT and BT compared to RP

Bladder CA EBRT BT 5-10 years 2.3 x 1.6 x Rectal CA EBRT EBRT + BT >10 years 1.8 x 3.3 x

Cancer after radiation is WORSE!!! Bostrom PJ et al. Bladder cancer after radiotherapy for prostate cancer: Detailed analysis of pathologic features and outcomes after cystectomy. J Urology. Jan 2008. 34 pts underwent cystectomy for bladder CA after receiving RT for prostate CA 86% EBRT 53% locally advanced in radiation group 36% locally advanced in control group

Quality of Life 2008 prospectively measured patient reported outcomes of 1201 patients and 625 spouses after RP (603), EBRT (292), or BT (306) 2003 to 2006 with 24 mo follow-up

2008 percent reporting at 24 months Prostatectomy EBRT BT Overall urinary problem Overall bowel problem Poor erections 7 % 11 % 16 % 1 % 11 % 8 % 58 % 60 % 51 %

Cost of Therapy Costs of outpatient visits, medications, and hospitalizations calculated. RP EBRT RP Cost 1 st 6 months $ 12,184 $ 24,204 Cumulative Costs $ 36,888 EBRT $ 59,455 Carroll PR et al. Cumulative cost pattern comparison of prostate cancer treatments. American Cancer Society 2006.

Conclusions Surgery offers the best staging, QOL, fewer complications, decreased risk of secondary malignancies Radiation is a viable option for patients unfit for surgery Robotic assisted surgery has decreased recovery time and blood loss Overall, must be a patient involved decision making process